



UNITED STATES PATENT AND TRADEMARK OFFICE

4L
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/598,563	06/05/2007	Zoser B. Salama	7014-230	7255
46002	7590	11/02/2007		
JOYCE VON NATZMER PEQUIGNOT + MYERS LLC 200 Madison Avenue Suite 1901 New York, NY 10016			EXAMINER HABTE, KAHSAY	
			ART UNIT 1624	PAPER NUMBER
			MAIL DATE 11/02/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/598,563	Applicant(s) SALAMA, ZOSER B.	
	Examiner Kahsay Habte	Art Unit 1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>6/5/07&12/26/06</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 1-15 are pending in this application.

Election/Restriction

2. Applicant's election with traverse of Group II (R1 and R2 together with the N atom to which they are attached form a morpholino ring) on 10/15/2007 is acknowledged. The traversal is on the ground that "the PCT state that the inclusion of more than one invention in one international application is permitted if all inventions are so linked as to form a single general inventive concept (Rule 13.1). With respect to a group of inventions claimed in an international application, unity of invention exists when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features". This is not found persuasive because the United States Patent and Trademark Office is *not* bound by the lack of unity determination by another International Searching Authority. MPEP 1875 states that whether or not the question of unity of invention has been raised by the International Searching Authority, it may be considered by the examiner when serving as an authorized officer of the International Preliminary Examining Authority. Thus, the Examiner is *not* bound by any previous determination made. In addition, 37 C.F.R. 1.484 indicates that the international preliminary examination is a non-binding opinion. Finally, 37 C.F.R. 1.499 states that, if the Examiner finds that a national stage application lacks unity of invention under 37 C.F.R. 1.475, the Examiner may in an Office action require the applicant in the response to that action to elect the invention to

Art Unit: 1624

which the claims shall be restricted. Thus, the determination of lack of unity is proper under the PCT treaty.

The requirement is still deemed proper and is therefore made FINAL.

3. The claims are drawn to multiple inventions for reasons set forth in the restriction requirement. The claims are examined only to the extent that they read on the elected invention. Cancellation of the non-elected subject matter is recommended in response to this Office Action.

Information Disclosure Statement

4. Applicant's Information Disclosure Statement, filed on 06/05/2007 and 12/26/2006 has been acknowledged. Please refer to Applicant's copies of the 1449 submitted herewith.

Note that the IDS submitted 06/05/2007 contain NPL reference that are databases from Beilstein and Caplus online (1-3 and 6-10) with no date and has not been considered. At least a year in which these references are available as a prior art should be provided in the 1449.

In regard to the IDS submitted on 10/26/2006, most of the references (Russian) submitted on page 2 of the IDS have not considered. Applicants have to submit the missing references.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.


Claims 1-6 and 13 are rejected under 35 U.S.C. 102(b) as being anticipated by Ergashev et al. Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1986), 29(1), 39-41. Cited reference teaches the following compounds that are the same as applicants. Applicants have cited this reference in the 1449.

Art Unit: 1624

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 106087-86-9 CAPLUS

CN 2-Butyn-1-ol, 4-(4-morpholinyl)-, propanoate (ester) (9CI) (CA INDEX NAME)




RN 106087-89-2 CAPLUS

CN Hexanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)



RN 106087-90-5 CAPLUS


CN Octanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)



Art Unit: 1624


RN 106087-87-0 CAPLUS

CN Butanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)



RN 106087-88-1 CAPLUS

CN Pentanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)




RN 106087-89-2 CAPLUS

CN Hexanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)

RN 106087-91-6 CAPLUS


CN Nonanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)



Art Unit: 1624

RN 106087-92-7 CAPLUS

CN Decanoic acid, 4-(4-morpholinyl)-2-butynyl ester (9CI) (CA INDEX NAME)



Said compounds are the same as applicants when applicants compound of formula I has the following substituents: R = alkyl.

6. Claims 1-12 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Ergashev et al. Khimiko-Farmatsevticheskii Zhurnal (1986), 20(9), 1050-1. The examiner has attached in this Office Action the abstract of said Russian reference in English that shows the prior art compound.

L4 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:27650 CAPLUS Full-text
DOCUMENT NUMBER: 106:27650
TITLE: Synthesis and hypocholesterolemic activity of
aminobutynyl linoleates
AUTHOR(S): Ergashev, M. S.; Makhsumov, A. G.; Khadzhiev, A. K.
CORPORATE SOURCE: Med. Inst., Tashkent, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1986), 20(9),
1050-1
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian

Art Unit: 1624

AB Me(CH₂)₄CH:CHCH₂CH:CH(CH₂)₇CO₂CH₂C.tplbond.CCH₂NR₂ (I, R = Et or CH₂Ph or NR₂ = piperidinyl or morpholinyl) were prepared from propargyl linoleate [106059-79-4], CH₂O and the appropriate amine. In studies in rabbits with exptl. atherosclerosis and hypercholesterolemia, I (NR₂ = morpholino) [106059-82-9] and I (R = CH₂Ph) [106059-83-0] were more active as hypocholesterolemic than were the other 2 compds. All were more effective than the hypocholesterolemic Arakhides.


IT 106059-82-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and hypocholesterolemic activity of)

RN 106059-82-9 CAPLUS

DN 9,12-Octadecadienoic acid (9Z,12Z)-, 4-(4-morpholinyl)-2-butynyl ester
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



This compound is the same as applicants because R = alkyl (unsaturated).

The examiner will provide the reference upon request.

7. Claims 1-12 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Makhsumov et al. Uzbeskii Khimicheski Zhurnal (1985), (5), 63-65. The examiner has attached in this Office Action the abstract of said Russian reference in English that shows the prior art compound.

Art Unit: 1624

L4 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2007 ACS on SIN

ACCESSION NUMBER: 1987:4504 CAPLUS Full-text
DOCUMENT NUMBER: 106:4504
TITLE: Amino ester acetylene derivatives of sorbic acid
AUTHOR(S): Makhsuimov, A. G.; Tadzhibaev, U.; Ergashev, M. S.
CORPORATE SOURCE: Tashk. Gos. Med. Inst., Tashkent, USSR
SOURCE: Uzbekskii Khimicheskii Zhurnal (1985), (5), 63-5
CODEN: UZKZAC; ISSN: 0042-1707
DOCUMENT TYPE: Journal

AB Mannich reaction of propargyl sorbate with R₂NH (R = hexyl, octyl, PhCH₂; R₂N = morpholino, anabasino, cytisino) and paraform in dioxane containing Cu(OAc)₂ at 100-105° gave 6 corresponding Me(CH:CH)2CO2CH2C.tplbond.CCH2NR2 in 76.1-92.1% yield.


IT 105566-28-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by Mannich reaction of propargyl sorbate)

RN 105566-28-7 CAPLUS

CN 2,4-Hexadienoic acid, 4-(4-morpholinyl)-2-butynyl ester, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



This compound is the same as applicants when applicant's compound of formula I has the following substituent R = alkyl (unsaturated).


The examiner will provide the reference upon request.

8. Claims 1-12 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Kruglikova et al. Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1974), 17(12), 1824-7. The examiner has attached in this Office Action the abstract of said Russian reference in English that shows the prior art compound.

Art Unit: 1624

L4 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1975:409070 CAPLUS Full-text
 DOCUMENT NUMBER: 83:9070
 TITLE: Synthesis of γ -substituted propargyl alcohols,
 their ethers and esters
 AUTHOR(S): Kruglikova, R. I.; Berestevich, B. K.; Babaeva, L. G.;
 Unkovskii, B. V.
 CORPORATE SOURCE: Mosk. Inst. Tonkoi Khim. Tekhnol. im. Lomonosova,
 Moscow, USSR
 SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i
 Khimicheskaya Tekhnologiya (1974), 17(12), 1824-7
 CODEN: IVUKAR; ISSN: 0579-2991
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian

AB RC.tplbond.CCH₂OH (R = Me, MeOCH₂, CH₂:CH, Ph, Me₂NCH₂, Me₂C(OH),
 1-hydroxycyclohexyl, PhCH(OH)) were prepared in 38-59% yield. E.g.,
 H₂C:CH₂C.tplbond.CCH₂OH was prepared by treatment of HC.tplbond.CCH:CH₂ with
 EtMgBr, followed by HCHO. R₁C.tplbond.CCH₂OMe (R₁ = H, Me, MeOCH₂, Ph,
 Me₂NCH₂, MeCO₂CH₂, ClCH₂, BrCH₂, MeC(OH)) were prepared in 39-85% yield,
 usually by methylation of the resp. alcs. RC.tplbond.CCH₂O₂CC₆H₄NO₂-p (R
 = H, Me, MeOCH₂, Ph, Me₂NCH₂, Br) and RC.tplbond.CCH₂O₂CPh (R = H, Me,
 MeOCH₂, CH₂:CH, Ph, 1-hydroxycyclohexyl, Me₂NCH₂, Et₂NCH₂,
 piperidinomethyl, morpholinomethyl) were prepared by standard methods.
 IT 54757-85-6P 54757-94-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 54757-85-6 CAPLUS
 CN 2-Butyn-1-ol, 4-(4-morpholinyl)-, benzoate (ester) (9CI) (CA INDEX NAME)



Art Unit: 1624

This compound is the same as applicants when applicant's compound of formula I has the following substituent R = phenyl. The examiner will provide the reference upon request.

9. Claims 1-12 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Abdurakhimov et al. Tr. Tashkent. Politekh. Inst. (1970), No. 64, 29-32. The examiner has attached in this Office Action the abstract of said Russian reference in English that shows the prior art compound.

L4 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1972:526576 CAPLUS Full-text
DOCUMENT NUMBER: 77:126576
ORIGINAL REFERENCE NO.: 77:20853a,20856a
TITLE: Condensation of propargyl palmitate with amines
AUTHOR(S): Abdurakhimov, A.; Makhsumov, A. G.; Safaev, A. S.;
Il'khamdzhanov, P.
CORPORATE SOURCE: USSR
SOURCE: Tr. Tashkent. Politekh. Inst. (1970), No. 64, 29-32
From: Ref. Zh., Khim. 1971, Abstr. No. 22Zh230
DOCUMENT TYPE: Journal
LANGUAGE: Russian


Art Unit: 1624

AB The maximum yield is obtained in the title reaction if HCHO is used, rather than (HCHO)_x, and Cu(OAc)₂ is used as catalyst. Thus, 0.015 mole 40% HCHO, 0.01 mole piperidine, 0.01 mole Me(CH₂)₁₄CO₂CH₂C.tplbond.CH, 40 ml dioxane, and 0.15 g Cu(OAc)₂ was heated 6 hr at 96-8° to give 83% Me(CH₂)₁₄CO₂CH₂C.tplbond.CCH₂R (R = piperidino). Similarly prepared was 82.8% morpholino analog.

IT 38022-01-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 38022-01-4 CAPLUS

CN Hexadecanoic acid, 4-(4-morpholinyl)-2-butyryl ester (9CI) (CA INDEX NAME)



This compound is the same as applicants when applicant's compound of formula I has the following substituent R = phenyl. The examiner will provide the reference upon request.

10. Claims 1-12 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Dahlbom et al. Acta Chemica Scandinavica (1963), 17, 916-20. The examiner has attached in this Office Action the abstract of said reference that shows the prior art compound.

Art Unit: 1624

L4 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1963:448341 CAPLUS Full-text

DOCUMENT NUMBER: 59:48341

ORIGINAL REFERENCE NO.: 59:8729h,8730a-b

TITLE: Acetylene compounds of potential pharmacological value. I. 4-Amino-2-butyryl esters of diphenylacetic acid, 1-phenylcyclopentane-1-carboxylic acid, and phenothiazine-10-carboxylic acid

AUTHOR(S): Dahlbom, Richard; Mollberg, Rene

CORPORATE SOURCE: Roy. Inst. Pharm., Stockholm

SOURCE: Acta Chemica Scandinavica (1963), 17, 916-20

CODEN: ACHSE7; ISSN: 0904-213X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB: Esters of diphenylacetic acid (I), 1-phenylcyclopentane-1-carboxylic acid (II), and phenothiazine-10-carboxylic acid (III) with RCH₂C.tplbond.CCH₂OH (IV) have been prepared, where R = NMe₂ (V), NEt₂ (VI), pyrrolidino (VII), piperidino (VIII), and morpholino (IX). IV was obtained from ClCH₂C.tplbond.CCH₂OH and the appropriate amine by the method of Biel (B., et al., CA 52, 6335g). Reported were IV (R, % yield, b.p./mm., and n_D²⁰ given): VII, 85, 112-13°/0.9, 1.5092; VIII, 71, 101-2°/0.4, 1.5043. A solution of 0.055 mole acid chloride, 0.05 mole IV, and 0.06 mole Et₃N in 50 ml. C₆H₆ was refluxed 3-20 hrs., then cooled, filtered, and concentrated in vacuo. The residue was dissolved in 50 ml. Et₂O, treated with HCl and the precipitate recrystd. from Et₂O-EtOH. Quaternary salts of III esters were also prepared. The following RCH₂C.tplbond.CCH₂R₁R₂X were obtained (RH, R₁, R₂X, % yield, and m.p. given): III, V, HCl, 48, 185-6° (decomposition); III, V, EtBr, 83, 158-9° (decomposition); III, VI, HCl, 61, 181-2° (decomposition); III, VI, MeBr, 91, 141-2° (decomposition); III, VII, HCl, 69, 155.5-6.5° (decomposition); III, VII, MeBr, 89, 163-4° (decomposition); III, VIII, HCl, 72, 176-7° (decomposition); III, VIII, MeBr, 98, 170-1° (decomposition); III, IX, HCl, 64, 188-9° (decomposition); II, V, HCl, 86, 144-6°; II, VI, HCl, 57, 92.5-4°; II, VIII, HCl, 65, 124-6°; II, IX, HCl, 71, 167-9°; I, VI, HCl, 79, 128-30°; I, VII, HCl, 83, 142-4°; I, VIII, HCl, 78, 158-60°; I, IX, HCl, 80, 160-1.5°.


II 97417-91-9 98075-12-8 98222-92-5

98249-62-8

(Derived from data in the 7th Collective Formula Index (1962-1966))

Art Unit: 1624

RN 95130-43-1 CAPLUS

IN Acetic acid, diphenyl-, 4-morpholino-2-butynyl ester, hydrochloride (7CI)
(CA INDEX NAME)

● HCl

This compound is the same as applicants when applicant's compound of formula I has the following substituent R = methyl substituted by phenyl. The examiner will provide the reference upon request.

Claim Rejections - 35 USC § 112

11. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 10-12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In claim 10, it is recited a method of treating a cell proliferative disorder including neoplasia (claim 11), but the specification is not enabled for such a scope.

A number of factors are relevant to whether undue experimentation would be required to practice the claimed invention, including "(1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims." In re Wands, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

(1). Breadth of Claims: Claims 10-12 are directed to a method of treating a cell proliferative disorder including neoplasia selected from leukemias, lymphomas, etc. that comprises administering to a patient benefiting from such treatment at least one compound of claim 1 or a pharmaceutically acceptable salt.

a. Scope of use - The scope of use that applicants intend to claim is very broad. To this day, it is impossible to treat a cell proliferative disorder with a single pharmaceutical drug. A proliferative disorder is anything that causes any abnormal tissue growth. That can be growth by cellular proliferation more rapidly than normal, or continued growth after the stimulus that initiated the new growth has ceased, or lack (partial or complete) of structural organization and/or coordination with surrounding tissue. It can be benign or malignant. Thus, such a term covers not only all cancers, but also covers precancerous conditions such as lumps, lesions, and polyps. In addition, it embraces

Art Unit: 1624

various non-cancerous proliferative disorders such as certain types of restenosis, vascular smooth muscle proliferation associated with atherosclerosis, glomerular nephritis, clonal proliferative disorders including the various Myelodysplastic Syndromes such as Refractory anemias, certain types of abnormal wound healings, different types of abnormal angiogenesis, pulmonary fibrosis, macular degeneration, myeloproliferative disorders such as primary polycythemia and myelofibrosis, and rheumatoid arthritis. There is no such thing that an agent which is effective against such disorders generally, since they are so diverse, nor is there any reason to think that such an agent could be made to work.

b. Scope of Compounds - The scope of the compounds is also broad. It is apparent that thousands of combinations of compounds can be created from the definitions, owing especially to broad scope of R and the substituents on the morpholine.

(2). Direction of Guidance: The amount of direction or guidance is minimal. There is no guidance in the specification for the treatment of cell proliferative disorder in general or neoplasia.

Art Unit: 1624

(3). State of Prior Art: There is no evidence of record that compounds structurally similar to these morpholinyl compounds of formula I are in use for the treatment of a cell proliferative disorder in general.

(4). Working Examples: The working examples at pages 71-74 discloses % inhibition growth data for L2, L4, L6, L9, L12-13 and L15-16, but there is no way to convert this data into specific useful knowledge, especially in view of the difficult nature of some of these disorders.

(5). Nature of the Invention and Predictability: The invention is directed to a method of treating a cell proliferative disorder. It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved," and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). Cell proliferative disorder are especially unpredictable due to their complex nature.

(6). The Quantity of Experimentation Necessary: Immense, because so many cell proliferative disorders are covered; see part (1).

(7). The Relative Skill of Those in the Art: The relative skill is extremely very low. To this day, there is no magic bullet that can treat all cell proliferative disorders in general.

Art Unit: 1624

When the best efforts have failed to achieve a goal, it is reasonable for the PTO to require evidence that such a goal has been accomplished, *In re Ferens*, 163 USPQ 609. The failure of skilled scientists to achieve a goal is substantial evidence that achieving such a goal is beyond the skill of practitioners in that art, *Genentech vs Novo Nordisk*, 42 USPQ2nd 1001, 1006.

It is recommended that applicants delete claims 10-12 to overcome this rejection.

Claim Rejections - 35 USC § 112

12. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention:

a. Claim 1 and claims dependent are rejected because the term "their bis-(2-butynyl)diesters" is not clear. What is covered and what is not? What is the definition of R for said diesters? Can R be a bond for said diesters?

b. In claim 1 (page 5, line 6), the phrase "can be replaced by 0, S or N" should read "can be replaced by O, S or N". Note that zero (0) should be changed to letter O.

c. In claims 9 and 14, the phrase "for use" is a mental step. Do applicants intend a composition claim or a method of use claim? If they intend a method of use claim, then the claim should be written as a method of use claim. It is recommended that applicants delete this phrase from claims 9 and 14.

d. In claim 10, the nomenclature of the compound is not clear. The compound M4-(N-substituted amino)-2-butyryl-1-ester starts with M4, but it is unclear what M4 stands for. Is M a typographical error?

e. In claim 10, the phrase "in a cell proliferative disorder treating effective amount" is not clear. The phrase appears to be garbled or incomplete.

Conclusion

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Art Unit: 1624

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read "Kahsay Habte". The signature is stylized with a large, sweeping initial "K" and "H".

Kahsay Habte
Primary Examiner
Art Unit 1624

KH
October 30, 2007